AccScience Publishing / CP / Volume 3 / Issue 3 / DOI: 10.18063/cp.v3i3.365
Cite this article
45
Download
906
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
CASE REPORT

Racotumomab Therapeutic Vaccine in the Treatment of Advanced Lung Cancer in the Elderly: A Case Report

Tatiana Hernández Casola* Héctor Luis Salazar Ferrer1 Isela Companioni de la Cruz1
Show Less
1 Hospital General Provincial Docente Capitán Roberto Rodríguez, Fernández, Cuba.
CP 2021, 3(3), 46–48; https://doi.org/10.18063/cp.v3i3.365
© Invalid date by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

We reported a clinical case of an 84-year-old smoker who was diagnosed with stage IV lung cancer and was included in the phase III clinical trial and treated with racotumomab. The patient had a an ECOG grade 0 according to the function scale. Therefore, it should be emphasized that this vaccine can improve the survival rate of patients with recurrent or advanced non-small cell lung cancer.

Keywords
Elderly
Non-small cell lung cancer
Therapeutic vaccine
Racotumomab
Phase III clinical trial
Survival rate
References

Martínez Feria F, Acosta Brooks SC, Cobián Caballero CO, 2015, Supervivencia libre de progresión de cáncer pulmonar de células no pequeñas en pacientes vacunados con CIMAvax-EGF [Progression-Free Survival of Non-small Cell Lung Cancer in Patients Vaccinated with CIMAvax-EGF]. Medisan, 19:1485–91.

Zalduendo P, 2016, Cáncer de pulmón. Síntomas, tipos, tratamiento y esperanza de vida [Lung Cancer: Symptoms, Types, Treatment and Life Expectancy]. Available from: https://www.enfermedadesgraves.com/blog/cancer-de-pulmon/.

De la Luz-Hernandez K, Rabasa Y, Montesinos R, et al., 2014, Cancer Vaccine Characteristics: From Bench to Clinic. Vaccines, 32:2851–8.

Noriega L, Bares JP, García E, et al., 2017, Factores de Riesgo y Tamizaje del Cáncer de Pulmón de Células No Pequeñas (CPCNP): 2do Consenso Nacional de la Sociedad Panameña de Oncología (Mesa 1) [Risk Factors and Screening of Non-small Cell Lung Cancer: Second National Consensus of the Panamanian Society of Oncology (Table 1)]. Rev Med Panamá, 37:2412–642X.

Wang Q, Huang H, Zeng X, et al., 2016, Single-Agent Maintenance Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Bayesian Network Meta-Analysis of 26 Randomized Controlled Trials. Peer J, 4:e2550.

Pérez Escobar MM, García Rodríguez ME, Armas Moredo K, et al., 2017, Cáncer de pulmón de células no pequeñas: presentación de caso [Non-Small Cell Lung Cancer: Case Report]. AMC, 21:258–63.

Gabri MR, Cacciavillano W, Chantada GL, et al., 2016, Racotumomab for Treating Lung Cancer and Pediatric Refractory Malignancies. Expert OpinBiol Ther, 16:573–8.

Maemondo M, Inoue A, Kobayashi K, et al., 2010, Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med, 362:2380–8.

Cobián Caballero CO, Acosta Brooks SC, Martínez Feria F, et al., 2016, Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF [Survival Rate of Patients With Non-Small Cell Lung Cancer Inoculated sith CIMAvax-EGF]. MEDISAN, 20:320–8.

Hernández AM, Rodríguez N, González JE, et al., 2011, Anti-NeuGcGM3 Antibodies, Actively Elicited by Idiotypic Vaccination in Nonsmall Cell Lung Cancer Patients, Induce Tumor Cell Death by an Oncosis-Like Mechanism. J Immunol, 186:3735–44.

Share
Back to top
Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing